Citigroup Maintains Buy on Medline, Lowers Price Target to $55
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Patrick Donnelly maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $60 to $55.
Citigroup analyst Patrick Donnelly maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $60 to $55.